NextCure faces a precarious outlook as it continues to operate without revenue, leading to a rapid erosion of its asset base from $128.0 million in 2023Q4 to $38.0 million in 2026Q1. The company's reliance on external funding to support volatile R&D expenditur...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$1.84+5.6% vs -$1.95 | — vs — |
Q2 2026 May 7, 2026 | -$1.87-3.3% vs -$1.81 | — vs — |
Q2 2026 Mar 5, 2026 | -$0.81+64.2% vs -$2.26 | — vs — |
Q4 2025 Nov 5, 2025 | -$3.22+20.7% vs -$4.06 | — vs — |
NextCure, Inc. (NASDAQ: NXTC - Get Free Report)'s stock price was up 7.7% during trading on Tuesday. The company traded as high as $8.64 and last traded at $8.42. 95,035 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 147,812 shares. The stock had previously closed at $7.82.
Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029 SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced a $500 million private placement (the "Private Placement") from a syndicate of leading healthcare investors. The Private Placement is in addition to the previously announced $320 million concurrent private investment, and the combined proceeds will support the continued development of Avere's lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.
NextCure, Inc. (NASDAQ: NXTC - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,323,834 shares, an increase of 734.7% from the June 30th total of 158,592 shares. Approximately 41.6% of the shares of the stock are short
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Benchmark NXTC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for NextCure, Inc. (NXTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.09 | $18.39M | -0.26 | — | — | -111.23% | — | |
| $2.32 | $270.42M | -2.02 | -51.24% | -1941.09% | -65.08% | — | |
| $24.44 | $3.07B | -7.43 | -4.26% | -386.32% | -87.98% | — | |
| $8.36 | $348.13M | -2458.82 | 10.37% | 69.76% | — | — | |
| $33.62 | $6.94B | -12.14 | — | -7585.86% | -69.59% | — | |
| $54.29 | $8.31B | 19.60 | 87.32% | 55.22% | 72.3% | — |
NextCure, Inc. (NXTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
NextCure, Inc. (NXTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 14, 2026·SEC
Jun 25, 2026·SEC
Get notified when NXTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NextCure, Inc. (NXTC) stock FAQ — growth, dividends, profitability & financials explained
NextCure, Inc. (NXTC) reported a net loss of $42.7M for fiscal year 2025.
NextCure, Inc. (NXTC) has a return on equity (ROE) of -111.2%. Negative ROE indicates the company is unprofitable.
NextCure, Inc. (NXTC) had negative free cash flow of $37.0M in fiscal year 2025, likely due to heavy capital investments.
